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Abstract Different neurological disorders, known as taupathies
have been recently described. In these disorders it has been
suggested that modifications in the microtubule-associated
protein tau could cause neural degeneration in specific regions.
Although these regions are different in the different taupathies,
some common features appear to occur in all of them: abnormal
hyperphosphorylation of tau and aberrant tau aggregation. These
two features are commented upon in this review. ß 2000 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
In the last decade there has been an increase in the descrip-
tion of neurodegenerative diseases in which aberrant ¢lamen-
tous inclusions are present in selected damaged populations of
nerve cells. These ¢lamentous inclusions are assembled from
proteins that, in non-pathological conditions, are in an unag-
gregated form [1]. Some of these neurological disorders have
in common that the protein aberrantly present in an aggre-
gated form is the microtubule-associated protein tau, a pro-
tein that is involved in microtubule stabilization [2,3]. Mice
lacking the tau protein can develop in a way similar to that of
wild-type mice [4] suggesting that its function may be substi-
tuted by other proteins.
The neural disorders or taupathies, in which tau is in an
aggregated form, have in common the presence of these aber-
rant tau aggregates. However, these aggregates may be
present in di¡erent types of neurons in each disorder. Among
the taupathies, the most studied is Alzheimer’s disease (AD), a
senile dementia, and the analyses of other types of dementia
with tau pathology (such as progressive supranuclear palsy
(PSP), Pick’s disease (PiD), corticobasal degeneration or fron-
totemporal dementias (FTD)), have usually been performed
by comparison with AD.
In AD, tau pathology (lack of binding to microtubules and
the formation of aberrant aggregates, neuro¢brillary tangles
(NFT)) has been correlated with the level of dementia [5]. In
addition, the development of ¢lamentous tau pathology in
speci¢c neural cells has been described. It starts in transento-
rhinal and entorhinal regions moving, later, to the hippocam-
pus and cortical regions [6,7]. It has been suggested that the
defects in a single cell, start with a modi¢cation of tau by
phosphorylation, giving place to a ‘pre-tangle’ stage [8]. After
this stage, ¢lamentous polymers (paired helical ¢laments,
PHF) are assembled and the aberrant aggregation of these
PHF results in the formation of cytoplasmic (intracellular)
NFT. As a consequence of this, it has been suggested that
neurons degenerate and die, thus leaving NFT in the extra-
cellular space [9,10]. The purpose of this review is mainly to
discuss the possible mechanisms involving the aberrant poly-
merization of tau into PHF and the formation of NFT.
2. Tau modi¢cations
Several abnormal modi¢cations have been described for tau
proteins present in the brain of AD patients. These modi¢ca-
tions include hyperphosphorylation [11,12], glycation [13,14],
ubiquitination [15], oxidation [16,17] and truncation [18].
Aberrant tau phosphorylation appears to be mainly involved
in the regulation of its binding to microtubules, decreasing it
[12], but not in facilitating tau assembly. Several kinases have
been involved in the anomalous hyperphosphorylation of tau
protein. These kinases have been divided into two groups:
proline- and non-proline-directed kinases [19]. Within the ¢rst
group, two kinases, ¢rst de¢ned as tau kinases I and II [20],
appear to play an important role. Tau kinase I corresponds to
GSK3 whereas tau kinase II is cdk5. GSK3 phosphorylation
of tau has been studied by di¡erent groups (i.e. [21,22]). This
kinase also interacts with other proteins, like presenilin-1, that
are important in the onset of AD pathology [23]. Cdk5 also
modi¢es tau protein and this kind of phosphorylation could
be deregulated in a neurodegenerative disorder like AD due to
proteolytic cleavage of the regulatory subunit, p35, of the ki-
nase [24]. Additionally, it has been suggested that another
kinase, cdc2, that is mainly present in proliferating cells, is
abnormally upregulated in AD [25] and that it could phos-
phorylate tau protein. The consequences of this phosphory-
lation could be a conformational change that prevents the
binding of phosphotau to microtubules. Binding has been
shown to be restored in the presence of a chaperone-like mol-
ecule, Pin-1 [26]. It is unknown if the conformational change
regulated by Pin-1 could also a¡ect tau aggregation.
Proline-directed phosphorylation mainly occurs at residues
located around the tubulin-binding region of the tau molecule
(see Fig. 1A). However, there are other non-proline-directed
kinases that phosphorylate tau at its tubulin-binding region.
These kinases are PKA, a novel MAPR kinase, and PKC
[12,27^29]. However, this type of phosphorylation appears
to play a role in AD but not in other taupathies like PiD.
Regarding the other modi¢cations, ubiquitination does not
appear to play a role in tau aggregation, the possible role of
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oxidation is discussed, truncation implicates the action of a
yet unknown protease and glycation is probably involved in
the aggregation of PHF into NFT but not in the formation of
¢laments.
3. Molecules that favor tau assembly into ¢laments polymers
Unmodi¢ed tau is able to self-aggregate in vitro in the
absence of other molecules [30^32], however, this requires a
very high concentration. To study if there are any molecules
that could facilitate tau assembly, some of the molecules that
are normally present in NFT were tested. Among these mol-
ecules were the sulfo-glycosaminoglycans (sGAG) [33]. In vi-
tro assembly of tau in the presence of sGAG, indicates that
the glycans facilitate tau polymerization [34,35], but only
those in sulfated form [35,36]. Thus, it appears that the
anionic nature of sGAG is essential for their function. Sim-
ilarly other polyanions also favor tau aggregation [37,38].
Although sGAG are present in intracellular NFT [33], it is
not known how they can be present in free form (not cova-
lently linked to a protein to form a proteoglycan) in the cy-
toplasm. Although the presence of free glycans in the cytosol
of some cells has been reported [39], this probably does not
occur in a neuron in non-pathological conditions. Thus, it has
been suggested that in pathological conditions, like AD,
sGAG could be present in the cytosol as a result of a leakage
from membrane compartments where sGAG and proteogly-
cans are normally present [10], since proteoglycans are deliv-
ered to the extracellular space into vesicles and are internal-
ized from the extracellular space by endocytosis by following
the endosome^lysosomal pathway. Possible abnormalities in
any of these subcellular structures could result in membrane
damage or in a dysfunction, and it was proposed that in AD
several lysosomal alterations could occur [40]. Moreover, the
injury of lysosome membranes in AD, probably by lipid per-
oxidation, has been reported [41,42]. These changes could be
related to the oxidative stress that may occur in AD, as pro-
posed by Smith et al. [43], since a possible de¢ciency of anti-
oxidants in AD could induce lysosomal disorders and result in
free radical formation. Nevertheless, more work should be
done to determine how sGAG interacts with tau protein in
the cytosol. On the other hand, it has been analyzed if
changes in the amount of sGAG, present in the extracellular
matrix, could have any correlation with the susceptibility of
the surrounding neurons to form NFT. In a recent report it
was concluded that there is a lower probability of forming
NFT in those neurons with a high proportion of sGAG,
like chondroitin sulfate, in their extracellular microenviron-
ment [44]. Thus, it could be suggested that those neurons
with less sGAG in their extracellular matrix have a higher
risk for tau pathology. Interestingly, it should be noted that
the interaction of factors like ¢broblast growth factor 2 or the
amyloid (AL) protein with their cell receptors are regulated by
the amount of sGAG in the extracellular matrix and that a
decrease in this amount could result in an increase in the
availability of these factors. Both of these factors upregulate
Fig. 1. A: Phosphorylation sites on tau molecule. The tau molecule
contains a proline-rich region (hatched) located adjacent to the tu-
bulin-binding region of the tau molecule. This tubulin-binding re-
gion is composed of four similar repeated sequences (numbers 1 to
4). Phosphorylation could take place by proline-directed (PDK) and
non-proline-directed kinases (NPDK) leading to hyperphosphoryla-
tion in AD. The major phosphorylation sites for PDK (b) and
NPDK (a) are indicated. Also shown is a phosphorylation site for
cdc2 kinase involved in the binding to Pin-1 (encircled b). B: Tau
regions mainly involved in microtubule binding and self-assembly.
The regions mainly involved in microtubule binding (mMTB) com-
prising the ¢rst and second tubulin-binding motifs and that mainly
involved in self-assembly (A) comprising part of the third tubulin
motif, are indicated. C: Location of tau mutations. The localization
in the tau molecule of di¡erent exonic mutations found in FTDP-17
are indicated.
Fig. 2. Tau interactions and modi¢cations. The tau protein may interact with di¡erent molecules (wide arrows) or may be modi¢ed in di¡erent
ways (normal arrows) that can be modulated by di¡erent proteins (interrupted arrows).
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GSK3 kinase activity [45,46]. Thus, these aspects on the
amount of sGAG in the extracellular matrix of neurons sus-
ceptible to forming NFT, should also be further analyzed.
In some taupathies like PSP, sGAG are not present in the
aberrant tau aggregates [47]. In these cases it has been sug-
gested that other molecules, involved in redox reactions, could
play a role in facilitating tau aggregation [47]. In any case, the
search for other molecules (or proteins) that could regulate
tau aggregation should be considered.
4. Tau mutations and tau polymerization
In one of the studied taupathies, the familial frontotempo-
ral dementia associated with a mutation in chromosome 17
where tau is present (FTDP-17), pathogenic tau gene muta-
tions have been observed, indicating that defects in the tau
gene are su⁄cient to form aggregates and to cause a neuro-
degenerative disorder [48].
In vitro tau polymerization, in the presence of sGAGs, has
been studied using di¡erent tau isoforms or fragments of the
tau molecule. These studies indicate that ‘big tau’, the isoform
that is mainly present in the peripheral nervous system, has a
lower capacity to polymerize than those tau isoforms present
in the central nervous system (our unpublished result). Addi-
tionally, it was observed that the minimal sequence of tau
protein that could form ¢laments is that containing residues
317 to 335, corresponding to the third tau repeat present in
the tubulin-binding region of the molecule (see Fig. 1B).
Changes in this sequence have indicated that residues 326
and 331 appear to be important for the polymerization of
the peptide. On the other hand the regions related to this
peptide (the other tau repeats present in the molecule) show
a much lower or no capacity to polymerize into ¢laments [49].
Tau mutations (see Fig. 1C) present in FTDP-17 have been
located mainly in the di¡erent tau repeats, except in the pep-
tide containing the minimal sequence needed for polymeriza-
tion [50^53], and it has been found that some of these muta-
tions favor tau polymerization in vitro [49,54,55]. However,
many of these mutations, like those present in the ¢rst and
second repeats, result in a decrease in the interaction of tau
with microtubules [56,57]. The P301L mutation is probably
the best example of the increase of tau polymerization in vitro
and those mutations located at the C-terminus may be in-
volved in altered tau phosphorylation (R406W). One yet un-
studied mutation (G389R) is very close to the possible trun-
cation site in the tau molecule [18] o¡ering a mechanism, that
could a¡ect tau aggregation [18].
5. Concluding remarks
Tau is a microtubule-associated protein that is involved in
microtubule stabilization, although mutants in this protein
develop in a normal way [4] probably because its function
can be replaced by other proteins. However, upon its aberrant
modi¢cation by phosphorylation, the modi¢ed tau could also
sequester some of those proteins [58] producing the break-
down of the microtubule network [59]. Additionally, abnor-
mal tau aggregation is found in taupathies like AD. Thus, two
main features are observed in tau pathology: microtubule
destabilization and tau polymerization. For the ¢rst feature,
the abnormal phosphorylation of tau could play a direct role,
whereas for tau aggregation it does not appear to in£uence it
in a direct way, whereas other factors like the presence of
other molecules or the mutation of the tau gene could facili-
tate tau aggregation. However, the combination of some of
these factors could facilitate a common conformational
change of tau protein that could a¡ect both tau microtubule
binding and tau aggregation. The binding of tau to micro-
tubules is mainly through the region comprising residues
241 to 304, whereas the minimal region needed for tau aggre-
gation contains the residues 317 to 335 (the indicated residues
are those of the longest central nervous system tau isoform
[60]). Thus, two di¡erent sequences are involved in the two
di¡erent features of tau pathology. This could be taken into
account for possible therapeutical approaches.
Finally, Fig. 2 shows the interaction of tau with di¡erent
molecules that could determine its localization (bound to mi-
crotubules), capacity of self-aggregation (sGAGs) or other
features that can result in its modi¢cation by phosphory-
lation, proteolysis, oxidation or glycation.
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